3rd Quarter - Report

MS. TAMI WAHL for ROCK & ASSOCIATES

Period 3rd Quarter 2018 Filed Oct 21, 2018 Signed by Tami L. Wahl

Official filing
Firm
MS. TAMI WAHL
Client
ROCK & ASSOCIATES
Income
$20,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Legislation impacting the operation of pharmacy compounding, and access to compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.

LobbyistCovered position, as disclosed
JAMES ROCK —
TAMI WAHL —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 2871 (115th)

Health Issues HCR

Legislation impacting the operation of pharmacy compounding, and access to compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.

LobbyistCovered position, as disclosed
JAMES ROCK —
TAMI WAHL —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2871 (115th)

Budget/Appropriations BUD

Appropriations to fund the implementation of regulations impacting pharmacy compounding.

LobbyistCovered position, as disclosed
JAMES ROCK —
TAMI WAHL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.